0
Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

±ÙÄ¡Àû Àü¸³¼±ÀýÁ¦¼úÀ̳ª È£¸£¸óÄ¡·á ÈÄÀÇ °Ç°­°ü·Ã »îÀÇ Áú°ú ¿ì¿ï

Health-related Quality of Life and Depression after Radical Prostatectomy or Hormonal Therapy

Á¾¾ç°£È£¿¬±¸ 2013³â 13±Ç 4È£ p.248 ~ 255
KMID : 1035120130130040248
¾ç±ÝÀÚ ( Yang Geum-Ja ) - ºÎ»ê´ëÇб³º´¿ø

°­Á¤Èñ ( Kang Jeong-Hee ) - ÀüºÏ´ëÇб³ °£È£´ëÇÐ
¼­Àμ± ( Suh In-Sun ) - ÀüºÏ´ëÇб³ °£È£´ëÇÐ
±èÇý¿µ ( Kim Hye-Young ) - ÀüºÏ´ëÇб³ °£È£´ëÇÐ

Abstract

Purpose: The aim of this study was to compare the health-related quality of life (HQOL) and depression in prostate cancer patients with radial prostatectomy or hormonal therapy more than 6 months ago.

Methods: A total of 116 patients participated in the study (83 radical prostatectomy patients and 33 hormonal therapy). Data were collected from 13th September to 13th November 2012, using two instruments-translated into Korean: Expanded Prostate Cancer Index Composite and Geriatric Depression Scale Short Form.

Results: Hormonal therapy participants reported significantly higher scores of HQOL than radical prostatectomy participants did (p=.002). The HQOL subscales with significant differences were urinary function (p<.001) and incontinence (p<.001) under urinary domain and sexual bother (p<.001) under sexual domain. The level of depression was not significantly different between the two treatment groups. There were moderate negative correlations between HQOL and depression in both groups.

Conclusion: Many of prostate cancer patients reported treatment-related functional deteriorations in urinary and sexual domains and they were depressed even more than 6 months after the treatment completion. To manage prostate cancer patients¡¯ HQOL and depression, clinicians including nurses should evaluate patients¡¯ complaints according to their treatment modality and intervene accordingly.
KeyWords
Àü¸³¼±¾Ï, »îÀÇ Áú, ¿ì¿ï, Àü¸³¼±ÀýÁ¦¼ú, È£¸£¸ó¿ä¹ý
Prostatic Neoplasms, Quality of Life, Depression, Prostatectomy, Hormone Replacement
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed